<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04125836</url>
  </required_header>
  <id_info>
    <org_study_id>HS-19-647</org_study_id>
    <secondary_id>2019-002190-66</secondary_id>
    <nct_id>NCT04125836</nct_id>
  </id_info>
  <brief_title>A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly</brief_title>
  <official_title>A Phase 3, Open-label, Single-arm, Multi-center Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With Acromegaly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Camurus AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Camurus AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to assess the long-term safety of CAM2029 in patients with
      acromegaly. Patients will be administered CAM2029 subcutaneously once monthly during 12
      months. Patients fulfilling trial NCT04076462 will be offered to continue with open-label
      treatment week 24-52 in this trial. Anticipate approximately 70 patients enrolled from start
      in this trial and approximately 70 patients to roll-over from trial NCT04076462.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Characterization of adverse events (AEs)</measure>
    <time_frame>Week 0-52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with mean IGF-1 levels ≤1xULN and ≤1.3xULN</measure>
    <time_frame>Week 50 to 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with mean GH levels &lt;2.5 µg/L and &lt;5.0 µg/L</measure>
    <time_frame>Week 50 to 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients/partners declared competent by a healthcare professional to administer intervention</measure>
    <time_frame>Week 0-52</time_frame>
    <description>During patients/partners first three attempts during the trial period of 52 weeks whenever these visits take place</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Octreotide plasma concentrations over time</measure>
    <time_frame>Week 0-52</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Acromegaly</condition>
  <arm_group>
    <arm_group_label>CAM2029 (octreotide subcutaneous depot)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CAM2029 (octreotide subcutaneous depot) 20mg/1.0 mL for 20 mg dose, subcutaneous injection once monthly, 12 months treatment. If down-titration is required, 10mg/0.5 mL for 10 mg dose is available.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAM2029 (octreotide subcutaneous depot)</intervention_name>
    <description>Octreotide subcutaneous depot for monthly injections in acromegaly patients</description>
    <arm_group_label>CAM2029 (octreotide subcutaneous depot)</arm_group_label>
    <other_name>CAM2029</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients, ≥18 years at screening

          -  Able to provide written informed consent to participate in the trial

          -  Diagnosis of acromegaly by historical evidence of (persistent or recurrent) acromegaly

          -  Treatment with a stable dose of octreotide LAR or lanreotide ATG for at least 3 months
             as monotherapy prior to screening

          -  IGF-1 levels ˃1xULN and ≤2.0xULN at screening or IGF-1 levels ≤1xULN at screening with
             prior pituitary radiotherapy

          -  Adequate liver, pancreatic, renal and bone marrow functions

          -  Normal ECG

        Exclusion Criteria:

        For Roll-over Patients from NCT04076462:

          -  Unresolved, drug-related serious adverse event (SAE) from the preceding trial

          -  Patients with a clinically significant or unstable medical or surgical condition that
             may preclude safe and complete trial participation

        For New Patients:

          -  Have received medical treatment for acromegaly with pasireotide (within 6 months prior
             to screening), pegvisomant (within 3 months prior to screening), dopamine agonists
             (within 3 months prior to screening) or other investigational agents (within 30 days
             or 5 half-lives prior to screening [whichever is longer]

          -  Patients who usually take octreotide LAR or lanreotide ATG less frequently than every
             4 weeks (e.g. every 6 weeks or 8 weeks)

          -  Patients with compression of the optic chiasm causing any visual field defect for whom
             surgical intervention is indicated

          -  Patients who have undergone major surgery/surgical therapy for any cause within 1
             month from screening

          -  Patients who have undergone pituitary surgery within 6 months prior to screening

          -  Patients who have received prior pituitary irradiation within 3 years prior to
             screening

          -  Patients with poorly controlled diabetes mellitus (hemoglobin A1c &gt;8.0%)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diego Ferone, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Genova Endocrinology Unit</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Camurus AB</last_name>
    <phone>+46 46 286 57 30</phone>
    <email>info@camurus.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katznelson</last_name>
      <email>katznels@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prufen Clinical Research LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Figueroa</last_name>
      <email>vfigueroa@prufenresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bancos</last_name>
      <email>bancos.irina@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10018</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Freda</last_name>
      <email>Puf1@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed</last_name>
      <email>Intekhab.Ahmed@jefferson.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allegheny Endocrinology Associates</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gordon</last_name>
      <email>mgordon740@msn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Institute of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brooks</last_name>
      <phone>214-265-2137</phone>
      <email>researcharonoff@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens &quot;Laiko&quot;, Endocrinology University Clinic</name>
      <address>
        <city>Athens</city>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaltsas</last_name>
      <email>gkaltsas@endo.gr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital of Thessaloniki &quot;Ippokratio&quot;</name>
      <address>
        <city>Thessaloníki</city>
        <zip>546 42</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SZTE ÁOK I.sz. Belgyógyászati Klinika</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magony</last_name>
      <email>magony.sandor@med.u-szeged.hu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Policlinico San Martino</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Universitaria &quot;Federico II&quot;</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AOUI Verona, Policlinic of GB Rossi</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Nowoczesnych Terapii &quot;Dobry Lekarz&quot;</name>
      <address>
        <city>Kraków</city>
        <zip>31-011</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sokolowski</last_name>
      <email>g.sokolowski@dobrylekarz.com.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Interregional Clinical Diagnostic Center</name>
      <address>
        <city>Ryazan'</city>
        <zip>420087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saratov Regional Clinic Hospital</name>
      <address>
        <city>Saratov</city>
        <zip>410053</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 11, 2019</study_first_submitted>
  <study_first_submitted_qc>October 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2019</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acromegaly</keyword>
  <keyword>octreotide</keyword>
  <keyword>CAM2029</keyword>
  <keyword>phase 3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acromegaly</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Octreotide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

